Impact of abdominal or pelvic radiotherapy on disease activity in inflammatory bowel disease: a multicentre cohort study from the GETAID.
Doriane BroussardPauline RiviereJoelle BonnetGinette FotsingAurélien AmiotLaurent Peyrin BirouletSylvie RajcaAnthony BuissonCyrielle GilletaAnne-Laure PelletierMelanie SerreroGuillaume BouguenRomain AltweggXavier HebuterneStephane NanceyMathurin FumeryGuillaume CadiotStephane NahonJean-Francois RahierJean-Marc GornetVeronique VendrelyDavid Laharienull nullPublished in: Alimentary pharmacology & therapeutics (2020)
Most patients with non-active IBD can be safely treated with abdominal or pelvic radiotherapy. Patients having acute gut toxicity and those without concomitant chemotherapy should be more closely monitored in the post-radiotherapy period.
Keyphrases
- locally advanced
- disease activity
- rectal cancer
- early stage
- rheumatoid arthritis
- end stage renal disease
- systemic lupus erythematosus
- radiation therapy
- newly diagnosed
- radiation induced
- rheumatoid arthritis patients
- chronic kidney disease
- ankylosing spondylitis
- ejection fraction
- squamous cell carcinoma
- liver failure
- juvenile idiopathic arthritis
- prognostic factors
- peritoneal dialysis
- oxidative stress
- study protocol
- randomized controlled trial
- patient reported outcomes
- intensive care unit
- respiratory failure
- drug induced